117 related articles for article (PubMed ID: 1709340)
1. Dysplastic melanocytic nevus. Immunohistochemical heterogeneity by melanosomal markers and S-100.
Salopek TG; Jimbow K
Am J Dermatopathol; 1991 Apr; 13(2):130-6. PubMed ID: 1709340
[TBL] [Abstract][Full Text] [Related]
2. Fine structural and immunohistochemical properties of dysplastic melanocytic nevi: comparison with malignant melanoma.
Jimbow K; Horikoshi T; Takahashi H; Akutsu Y; Maeda K
J Invest Dermatol; 1989 May; 92(5 Suppl):304S-309S. PubMed ID: 2715663
[TBL] [Abstract][Full Text] [Related]
3. Positive reactivity of dysplastic melanocytes with a monoclonal antibody against melanoma melanosomes, MoAb HMSA-2.
Maeda K; Maeda K; Jimbow K
J Invest Dermatol; 1988 Sep; 91(3):247-50. PubMed ID: 3411143
[TBL] [Abstract][Full Text] [Related]
4. Development of MoAb HMSA-2 for melanosomes of human melanoma and its application to immunohistopathologic diagnosis of neoplastic melanocytes.
Maeda K; Jimbow K
Cancer; 1987 Feb; 59(3):415-23. PubMed ID: 3539311
[TBL] [Abstract][Full Text] [Related]
5. A murine monoclonal antibody, MoAb HMSA-5, against a melanosomal component highly expressed in early stages, and common to normal and neoplastic melanocytes.
Der JE; Dixon WT; Jimbow K; Horikoshi T
Br J Cancer; 1993 Jan; 67(1):47-57. PubMed ID: 7678981
[TBL] [Abstract][Full Text] [Related]
6. Development and characterization of a mouse monoclonal antibody, MoAb HMSA-1, against a melanosomal fraction of human malignant melanoma.
Akutsu Y; Jimbow K
Cancer Res; 1986 Jun; 46(6):2904-11. PubMed ID: 3516387
[TBL] [Abstract][Full Text] [Related]
7. Development of MoAb HMSA-3 and HMSA-4 against human melanoma melanosomes and their reactivities on formalin-fixed melanoma tissues.
Maeda K; Yamana K; Jimbow K
J Invest Dermatol; 1987 Dec; 89(6):588-93. PubMed ID: 3680982
[TBL] [Abstract][Full Text] [Related]
8. Nature and biosynthesis of structural matrix protein in melanosomes: melanosomal structural protein as differentiation antigen for neoplastic melanocytes.
Jimbow K; Yamana K; Akutsu Y; Maeda K
Prog Clin Biol Res; 1988; 256():169-82. PubMed ID: 3368488
[TBL] [Abstract][Full Text] [Related]
9. The usefulness of tyrosinase in the immunohistochemical assessment of melanocytic lesions: a comparison of the novel T311 antibody (anti-tyrosinase) with S-100, HMB45, and A103 (anti-melan-A).
Clarkson KS; Sturdgess IC; Molyneux AJ
J Clin Pathol; 2001 Mar; 54(3):196-200. PubMed ID: 11253130
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of human monoclonal antibody (2-139-1) in cutaneous melanocytic neoplasms in fixed tissue sections.
White WL; Tam ST; Mitchell MS; Yu MC; Kan-Mitchell J
J Histochem Cytochem; 1991 Jun; 39(6):777-85. PubMed ID: 1709658
[TBL] [Abstract][Full Text] [Related]
11. WT1 and Bcl2 expression in melanocytic lesions of the conjunctiva: an immunohistochemical study of 123 cases.
Furusato E; Hidayat AA; Man YG; Auerbach A; Furusato B; Rushing EJ
Arch Ophthalmol; 2009 Aug; 127(8):964-9. PubMed ID: 19667332
[TBL] [Abstract][Full Text] [Related]
12. Complementary expression of melanosomal antigens and constant expression of pigment-independent antigen during the evolution of melanocytic tumours.
Takahashi H; Parsons PG; Favier D; McEwan M; Strutton GM; Akutsu Y; Jimbow K
Virchows Arch A Pathol Anat Histopathol; 1990; 416(6):513-9. PubMed ID: 2110698
[TBL] [Abstract][Full Text] [Related]
13. HMB-45 staining of dysplastic nevi. Support for a spectrum of progression toward melanoma.
Smoller BR; McNutt NS; Hsu A
Am J Surg Pathol; 1989 Aug; 13(8):680-4. PubMed ID: 2473661
[TBL] [Abstract][Full Text] [Related]
14. [Distribution of melanoma-associated antigens (HMB 45 and S 100) in benign and malignant melanocytic tumors of the conjunctiva].
Steuhl KP; Rohrbach JM; Knorr M
Klin Monbl Augenheilkd; 1991 Sep; 199(3):187-91. PubMed ID: 1753671
[TBL] [Abstract][Full Text] [Related]
15. Immunohistochemical detection of melanoma-associated antigens on formalin-fixed, paraffin-embedded canine tumors.
Berrington AJ; Jimbow K; Haines DM
Vet Pathol; 1994 Jul; 31(4):455-61. PubMed ID: 7941235
[TBL] [Abstract][Full Text] [Related]
16. Melanoma associated with a dysplastic nevus: report of two cases with unusual sebocyte-like melanocytes in the nevus part of the lesion.
Vazmitel M; Michal M; Mukensnabl P; Kazakov DV
Am J Dermatopathol; 2007 Dec; 29(6):566-7. PubMed ID: 18032954
[TBL] [Abstract][Full Text] [Related]
17. Immunohistochemical demonstration of S-100 protein and melanoma-associated antigens in melanocytic nevi.
Paul E; Cochran AJ; Wen DR
J Cutan Pathol; 1988 Jun; 15(3):161-5. PubMed ID: 2456315
[TBL] [Abstract][Full Text] [Related]
18. Microphthalmia transcription factor expression in cutaneous benign, malignant melanocytic, and nonmelanocytic tumors.
King R; Googe PB; Weilbaecher KN; Mihm MC; Fisher DE
Am J Surg Pathol; 2001 Jan; 25(1):51-7. PubMed ID: 11145251
[TBL] [Abstract][Full Text] [Related]
19. Ex vivo quality-switched ruby laser irradiation of cutaneous melanocytic lesions: persistence of S-100-, HMB-45- and Masson-positive cells.
Kopera D; Hohenleutner U; Stolz W; Landthaler M
Dermatology; 1997; 194(4):344-50. PubMed ID: 9252755
[TBL] [Abstract][Full Text] [Related]
20. Significance, specificity, and ultrastructural localization of HMB-45 antigen in pigmented ocular tumors.
Steuhl KP; Rohrbach JM; Knorr M; Thiel HJ
Ophthalmology; 1993 Feb; 100(2):208-15. PubMed ID: 8437829
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
